Who is sponsoring NCT03323866?

NCT03323866 is sponsored by Université de Sherbrooke.

What drugs are being tested in NCT03323866?

Interventions in NCT03323866: Budesonide 0.5 MG/ML, Mometasone nasal spray.

What condition does NCT03323866 study?

NCT03323866 studies Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis.

Is NCT03323866 still recruiting?

NCT03323866 is currently terminated. Last updated 21 September 2022.

Last reviewed 2022-09-21 · How we verify

NCT03323866

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mometasone vs Budesonide in CRS With Polyposis

Terminated Phase 3 Last updated 21 September 2022

What this trial tests

Phase 3 trial testing Budesonide 0.5 MG/ML in Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis in 36 participants. Terminated before completion.

Timeline

1 May 2017

Primary endpoint
1 May 2022

1 August 2022

Quick facts

Lead sponsor	Université de Sherbrooke
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	36
Start date	1 May 2017
Primary completion	1 May 2022
Estimated completion	1 August 2022
Sites	1 location across Canada

Drugs / interventions tested

Budesonide 0.5 MG/ML — full drug profile →
Mometasone nasal spray — full drug profile →

Conditions studied

Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis — all drugs for Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis →

Sponsor

Université de Sherbrooke — full company profile →

Who can join

18 and older, any sex, with Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The principal objective is to compare the use of mometasone nasal spray to budesonide irrigations in patients suffering from CRSwNP who have never been operated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Budesonide 0.5 MG/ML

Trials testing the same drug.

NCT04862377 — Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia. · Phase 3 · unknown

Other Université de Sherbrooke trials

Trials by the same sponsor.

NCT07524764 — Female Reproductive Health in Canadian Armed Forces · not yet recruiting
NCT07511842 — REST-Knee: A Pilot RCT of 72-Hour Knee Immobilization and Pain Outcomes · NA · recruiting
NCT07360587 — Thyroid Artery Embolization for the Treatment of Compressive Goiters. · NA · recruiting
NCT07396857 — The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting · NA · recruiting
NCT07122531 — Recovery With Exogenous Ketones and Antipsychotics · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03323866 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Université de Sherbrooke
Last refreshed: 21 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03323866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing